Evaluation and management of coronary artery disease in patients undergoing transcatheter aortic valve implantation

Abstract

Significant coronary artery disease (CAD) and severe aortic stenosis (AS) are frequent findings in patients who undergo transcatheter aortic valve implantation (TAVI). With the extension of TAVI in patients who have intermediate and even low surgical risk, the optimal evaluation and management of concomitant CAD needs to be determined. Both pre-TAVI evaluation of CAD and indications for revascularization remain a matter of debate. In this review, we provide an updated overview of the prevailing landscape of CAD in patients undergoing TAVI with a focus on its prognostic impact, diagnostic evaluation pre-procedure, indications for revascularization, optimal timing of revascularization, and future directions.

Keywords

Coronary artery disease / aortic stenosis / transcatheter aortic valve implantation / revascularization / percutaneous coronary intervention

References

[1] Rahim H,George I.The management of stable coronary artery disease and transcatheter aortic valve replacement.Struct Heart2021;5:439-45

[2] Adams DH,Reardon MJ.Transcatheter aortic-valve replacement with a self-expanding prosthesis.N Engl J Med2014;370:1790-8

[3] Popma JJ,Yakubov SJ.Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients.N Engl J Med2019;380:1706-15

[4] Walther T,Schuler G.Perioperative results and complications in 15,964 transcatheter aortic valve replacements: prospective data from the GARY registry.J Am Coll Cardiol2015;65:2173-80

[5] Otto CM,Bonow RO.2020 ACC/AHA Guideline for the management of patients with valvular heart disease: a report of the american college of cardiology/american heart association joint committee on clinical practice guidelines.Circulation2021;143:e72-227

[6] Tang GHL,Bhatt DL.Transcatheter aortic valve replacement in low-risk patients: a new era in the treatment of aortic stenosis.Circulation2019;140:801-3

[7] Lim GB.Suitability of TAVI in low-risk patients.Nat Rev Cardiol2023;20:284

[8] Cangemi S,Romagnoli E.Management of concomitant coronary artery disease and aortic valve stenosis in the era of transcatheter aortic valve treatment.Mini-Invasive Surg2022;6:3

[9] Sankaramangalam K,Kandregula K.Impact of coronary artery disease on 30-day and 1-year mortality in patients undergoing transcatheter aortic valve replacement: a meta-analysis.J Am Heart Assoc2017;6:e006092 PMCID:PMC5721835

[10] Safarian H,Shafiee A,Poorhosseini H.The SYNTAX score can predict major adverse cardiac events following percutaneous coronary intervention.Heart Views2014;15:99-105 PMCID:PMC4348991

[11] Puymirat E,Eltchaninoff H.Impact of coronary artery disease in patients undergoing transcatheter aortic valve replacement: insights from the FRANCE-2 registry.Clin Cardiol2017;40:1316-22 PMCID:PMC6490315

[12] D'Ascenzo F,Visconti M.Independent impact of extent of coronary artery disease and percutaneous revascularisation on 30-day and one-year mortality after TAVI: a meta-analysis of adjusted observational results.EuroIntervention2018;14:e1169-77

[13] Witberg G,Codner P,Kornowski R.Impact of coronary artery revascularization completeness on outcomes of patients with coronary artery disease undergoing transcatheter aortic valve replacement: a meta-analysis of studies using the residual SYNTAX score (synergy between PCI with taxus and cardiac surgery).Circ Cardiovasc Interv2018;11:e006000

[14] Stefanini GG,Cao D.Coronary artery disease severity and aortic stenosis: clinical outcomes according to SYNTAX score in patients undergoing transcatheter aortic valve implantation.Eur Heart J2014;35:2530-40

[15] Khawaja MZ,Haran H.The effect of coronary artery disease defined by quantitative coronary angiography and SYNTAX score upon outcome after transcatheter aortic valve implantation (TAVI) using the Edwards bioprosthesis.EuroIntervention2015;11:450-5

[16] de Azevedo Filho AF, Accorsi TA, Ribeiro HB. Coronary artery disease in patients with aortic stenosis and transcatheter aortic valve implantation: implications for management.Eur Cardiol2021;16:e49 PMCID:PMC8674631

[17] Chieffo A,Spagnolo P.Routine screening of coronary artery disease with computed tomographic coronary angiography in place of invasive coronary angiography in patients undergoing transcatheter aortic valve replacement.Circ Cardiovasc Interv2015;8:e002025

[18] van den Boogert TPW,Claessen BEPM.CTCA for detection of significant coronary artery disease in routine TAVI work-up: a systematic review and meta-analysis.Neth Heart J2018;26:591-9 PMCID:PMC6288031

[19] van den Boogert TPW,Opolski MP.DEtection of ProxImal coronary stenosis in the work-up for Transcatheter aortic valve implantation using CTA (from the DEPICT CTA collaboration).Eur Radiol2022;32:143-51 PMCID:PMC8660749

[20] Mathew RC,Salerno M.Computed tomography fractional flow reserve to guide coronary angiography and intervention.Interv Cardiol Clin2018;7:345-54 PMCID:PMC6553476

[21] Michail M,Comella A.Feasibility and validity of computed tomography-derived fractional flow reserve in patients with severe aortic stenosis: the CAST-FFR study.Circ Cardiovasc Interv2021;14:e009586 PMCID:PMC7116852

[22] Peper J,Kelder JC.Added value of computed tomography fractional flow reserve in the diagnosis of coronary artery disease.Sci Rep2021;11:6748 PMCID:PMC7991632

[23] Kalisz K,Saboo SS,Halliburton S.Artifacts at cardiac CT: physics and solutions.Radiographics2016;36:2064-83

[24] Vahanian A,Praz F.2021 ESC/EACTS guidelines for the management of valvular heart disease: developed by the task force for the management of valvular heart disease of the European society of cardiology (ESC) and the European association for cardio-thoracic surgery (EACTS).Eur Heart J2021;43:561-632

[25] Stanojevic D,Tadros P.Intravenous adenosine infusion is safe and well tolerated during coronary fractional flow reserve assessment in elderly patients with severe aortic stenosis.J Invasive Cardiol2016;28:357-61

[26] Katta N,Kalra A.Management of coronary artery disease in the setting of transcatheter aortic valve replacement.Heart Int2020;14:24-8 PMCID:PMC9524713

[27] Ahmad Y,Cook C.Coronary hemodynamics in patients with severe aortic stenosis and coronary artery disease undergoing transcatheter aortic valve replacement: implications for clinical indices of coronary stenosis severity.JACC Cardiovasc Interv2018;11:2019-31 PMCID:PMC6197079

[28] Pesarini G,Zivelonghi C.Functional assessment of coronary artery disease in patients undergoing transcatheter aortic valve implantation: influence of pressure overload on the evaluation of lesions severity.Circ Cardiovasc Interv2016;9:e004088

[29] Götberg M,Sen S,Escaned J.The evolving future of instantaneous wave-free ratio and fractional flow reserve.J Am Coll Cardiol2017;70:1379-402

[30] Scarsini R,Lunardi M.Observations from a real-time, iFR-FFR “hybrid approach” in patients with severe aortic stenosis and coronary artery disease undergoing TAVI.Cardiovasc Revasc Med2018;19:355-9

[31] Nishimura RA,Bonow RO.2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American college of cardiology/American heart association task force on practice guidelines.J Am Coll Cardiol2014;63:2438-88

[32] Faroux L,Wintzer-Wehekind J.Coronary artery disease and transcatheter aortic valve replacement: JACC state-of-the-art review.J Am Coll Cardiol2019;74:362-72

[33] Kotronias RA,George S.Transcatheter aortic valve implantation with or without percutaneous coronary artery revascularization strategy: a systematic review and meta-analysis.J Am Heart Assoc2017;6:e005960 PMCID:PMC5669191

[34] Lateef N,Deo SV.Meta-analysis comparing outcomes in patients undergoing transcatheter aortic valve implantation with versus without percutaneous coronary intervention.Am J Cardiol2019;124:1757-64 PMCID:PMC7453960

[35] Maron DJ,Reynolds HR.Initial invasive or conservative strategy for stable coronary disease.N Engl J Med2020;382:1395-407

[36] Khawaja MZ,Pocock S,Thomas MR.The percutaneous coronary intervention prior to transcatheter aortic valve implantation (ACTIVATION) trial: study protocol for a randomized controlled trial.Trials2014;15:300 PMCID:PMC4132914

[37] Patterson T,Dodd M.ACTIVATION (PercutAneous coronary inTervention prIor to transcatheter aortic VAlve implantaTION): a randomized clinical trial.JACC Cardiovasc Interv2021;14:1965-74

[38] Witberg G,Chen S.The prognostic effects of coronary disease severity and completeness of revascularization on mortality in patients undergoing transcatheter aortic valve replacement.JACC Cardiovasc Interv2017;10:1428-35

[39] Witberg G,Harari E.Effect of coronary artery disease severity and revascularization completeness on 2-year clinical outcomes in patients undergoing transcatether aortic valve replacement.Coron Artery Dis2015;26:573-82

[40] Biscaglia S,Escaned J.Complete or culprit-only PCI in older patients with myocardial infarction.N Engl J Med2023;389:889-98

[41] Doenst T,Serruys P.PCI and CABG for treating stable coronary artery disease: JACC review topic of the week.J Am Coll Cardiol2019;73:964-76

[42] Weferling M,Kim WK.Percutaneous coronary intervention in transcatheter aortic valve implantation patients: overview and practical management.Front Cardiovasc Med2021;8:653768 PMCID:PMC8129193

[43] Lim Y,Kuntjoro I,Yip J.Coronary artery disease in patients undergoing transvalvular aortic valve implantation.Interv Cardiol2022;17:e13 PMCID:PMC9585643

[44] van Rosendael PJ,Kamperidis V.Timing of staged percutaneous coronary intervention before transcatheter aortic valve implantation.Am J Cardiol2015;115:1726-32

[45] Kotronias RA,Bagur R.Revascularizing coronary artery disease in patients undergoing transcatheter aortic valve implantation.J Thorac Dis2018;10:E79-82 PMCID:PMC5863122

[46] Singh V,Thakkar B.Comparison of outcomes of transcatheter aortic valve replacement plus percutaneous coronary intervention versus transcatheter aortic valve replacement alone in the United States.Am J Cardiol2016;118:1698-704

[47] Barbanti M,Costa G.Optimized screening of coronary artery disease with invasive coronary angiography and Ad hoc percutaneous coronary intervention during transcatheter aortic valve replacement.Circ Cardiovasc Interv2017;10:e005234

[48] Bao L,Chen S.Feasibility and safety of combined percutaneous coronary intervention among high-risk patients with severe aortic stenosis undergoing transcatheter aortic valve implantation: a systematic review and meta-analysis.Eur J Cardiothorac Surg2018;54:1052-9

[49] Ochiai T,Flint N.Timing and outcomes of percutaneous coronary intervention in patients who underwent transcatheter aortic valve implantation.Am J Cardiol2020;125:1361-8

[50] Rheude T,Ribichini FL.Comparison of different percutaneous revascularisation timing strategies in patients undergoing transcatheter aortic valve implantation.EuroIntervention2023;19:589-99

[51] Tarantini G,Nai Fovino L.Management of coronary artery disease in patients undergoing transcatheter aortic valve implantation. A clinical consensus statement from the European association of percutaneous cardiovascular interventions in collaboration with the ESC working group on cardiovascular surgery.EuroIntervention2023;19:37-52 PMCID:PMC10174192

[52] Khokhar AA,Zlahoda-Huzior A.Coronary access following ACURATE neo implantation for transcatheter aortic valve-in-valve implantation: ex vivo analysis in patient-specific anatomies.Front Cardiovasc Med2022;9:902564 PMCID:PMC9515364